leisure time -WSS

leisure time

author：comprehensive 2025-08-12 09:11:02 - browse：31361

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Life science postdocs should get big pay hike, NIH panel says

hotspot

entertainment

WSS

Boston Scientific acquires urology company Axonics for $3.7 billion

Antibody drugs appear effective. Now can we make enough of them?

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

A Greenpeace activist is fined for crash

A Greenpeace activist is fined for crash

focus

leisure time

hotspot

The high cost of giving birth even with insurance

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Malaria cases in Florida and Texas: Here’s what you need to know

Merck to acquire Harpoon Therapeutics for $680 million

Activists slam private health insurers over coverage restrictions

Ascension's ugly legal battle over care for poor patients in Texas

Drug repurposing or repositioning? The language matters

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

23andMe had bad news about my health. I wish a person had delivered it

Male doctors called my cancer incurable. A female doctor showed it wasn't

hotspot

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

EU fines Illumina $475 million over Grail acquisition

JPM pitch from hospitals? Revenue streams outside of patient care

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Life science postdocs should get big pay hike, NIH panel says

hotspot

leisure time

entertainment

hotspot